Stratrix
On the Record · Hims & Hers Health

Hims & Hers Health acquisitions, on the record

The businesses Hims & Hers Health bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

BusinessDealWhenValue
YoDerm, Inc. ("Apostrophe")
Word for word“In July 2021, we completed our acquisition of YoDerm, Inc. (“Apostrophe”), allowing us to expand personalized dermatological offerings to our customers.” 10-K for 2023
acquisitionJuly 2021—
Honest Health Limited (now Hims & Hers UK Limited, "HHL")
Word for word“We expanded into the United Kingdom in early 2021, and in June 2021, we completed our acquisition of U.K.-based Honest Health Limited, which is now Hims & Hers UK Limited (“HHL”), a company that offers health and wellness products and services.” 10-K for 2023
acquisitionJune 2021—
Seaview Enterprises, LLC (d/b/a MedisourceRx) ("MedisourceRx")
Word for word“In 2024, we acquired Seaview Enterprises, LLC (d/b/a MedisourceRx) (“MedisourceRx”), a licensed 503B compounding outsourcing facility, which compounds products primarily for Hims & Hers customers (our “Outsourcing Facility”).” 10-K for 2024
acquisitionIn 2024—
Sigmund NJ, LLC, marketed as Trybe Labs ("Lab Facility")
Word for word“Also in February 2025, we acquired Sigmund NJ, LLC, marketed as Trybe Labs, a lab testing services business, which will allow us to add lab testing capabilities to our platform in the future (our “Lab Facility”).” 10-K for 2024
acquisitionFebruary 2025—
Seaview Enterprises LLC (d/b/a MedisourceRx)
Word for word“In September 2024, we satisfied all closing conditions of the executed purchase agreement to acquire all of the membership interests of Seaview Enterprises LLC (d/b/a MedisourceRx) (“MedisourceRx”), a 503B compounding outsourcing facility registered with the Food and Drug Administration and located in the United States , for total cash and stock consideration of approximately $31.0 million, including cash payments of $15.5 million and Class A common stock of $15.5 million.” 10-K for 2024
acquisitionIn September 2024approximately $31.0 million
Zava
Word for word“For instance, in July 2025, we completed the acquisition of Zava, a digital health platform with operations in the United Kingdom, Germany, Republic of Ireland, France, and Spain, and in November 2025, we completed the acquisition of Medici, a digital health platform with operations in Canada.” 10-K for 2025
acquisitionJuly 2025—
Medici
Word for word“For instance, in July 2025, we completed the acquisition of Zava, a digital health platform with operations in the United Kingdom, Germany, Republic of Ireland, France, and Spain, and in November 2025, we completed the acquisition of Medici, a digital health platform with operations in Canada.” 10-K for 2025
acquisitionNovember 2025—
Eucalyptus
Word for word“The aggregate total consideration of the transaction is up to $1.15 billion, subject to certain adjustments set forth in the Deed (the “Proposed Acquisition”).” 10-K for 2025
agreed acquisition—up to $1.15 billion
licensed 503B outsourcing facility
Word for word“In May 2024, we began offering access to GLP-1s as part of our weight loss offering, first in the form of compounded injectable semaglutide, and in September 2024, we acquired a licensed 503B outsourcing facility.” 10-K for 2025
acquisitionSeptember 2024—
As filedReported in the company's financial data (XBRL), each linked to its filing
Fiscal year endedCash paid for acquisitions (net of cash acquired)Goodwill from acquisitions
2019-12-31$0—
2020-12-31$0—
2021-12-31$46.5 million$110.9 million
2022-12-31$0—
2023-12-31$0—
2024-12-31$15.4 million$1.8 million
2025-12-31$145.2 million$165.3 million

Deal filings since 2016

Read from Hims & Hers Health’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-23. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.